Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6931 to 6945 of 8314 results

  1. Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]

    Discontinued Reference number: GID-TA10065

    Technology appraisal guidance
    Discontinued

  2. Etirinotecan pegol for treating breast cancer with brain metastases [ID881]

    Discontinued Reference number: GID-TA10066

    Technology appraisal guidance
    Discontinued

  3. Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]

    Discontinued Reference number: GID-TA10070

    Technology appraisal guidance
    Discontinued

  4. Melanoma (advanced, unresectable, metastatic, NRAS mutation positive) - binimetinib [ID833]

    Discontinued Reference number: GID-TA10074

    Technology appraisal guidance
    Discontinued

  5. Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]

    Discontinued Reference number: GID-TA10081

    Technology appraisal guidance
    Discontinued

  6. Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin's lymphoma [ID1044]

    Discontinued Reference number: GID-TA10087

    Technology appraisal guidance
    Discontinued

  7. Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]

    Discontinued Reference number: GID-TA10088

    Technology appraisal guidance
    Discontinued

  8. Biotin for treating primary and secondary progressive multiple sclerosis [ID919]

    Discontinued Reference number: GID-TA10099

    Technology appraisal guidance
    Discontinued

  9. Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]

    Discontinued Reference number: GID-TA10105

    Technology appraisal guidance
    Discontinued

  10. Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]

    Discontinued Reference number: GID-TA10109

    Technology appraisal guidance
    Discontinued

  11. Pembrolizumab for treating relapsed metastatic colorectal cancer with high microsatellite instability [ID1071]

    Discontinued Reference number: GID-TA10110

    Technology appraisal guidance
    Discontinued

  12. Nivolumab for treating recurrent glioblastoma [ID998]

    Discontinued Reference number: GID-TA10126

    Technology appraisal guidance
    Discontinued

  13. Pacritinib for treating myelofibrosis [ID880]

    Discontinued Reference number: GID-TA10133

    Technology appraisal guidance
    Discontinued

  14. Elotuzumab for untreated multiple myeloma [ID966]

    Discontinued Reference number: GID-TA10134

    Technology appraisal guidance
    Discontinued

  15. Nintedanib for previously treated metastatic colorectal cancer [ID1030]

    Discontinued Reference number: GID-TA10138

    Technology appraisal guidance
    Discontinued